Dendritic Cell - Tumor Cell Fusion Hybrid Vaccine

CyTIX creates Multiple Antigen Presenting Cell to induce CD8+ T-Cell to attack Cancer Cell

"Presentation" for BIO Europe Spring 2016

CyTIX is a biotech company developing "Dendritic Cell" based immuno therapy cancer vaccine. Combination therapy with "Dendritic Cell Tumor Cell Fusion Hybrid Vaccine" and "Interleukin 12" is our main treatment which is the platform for the most of all indications of solid tumors. Unlike other DC vaccine which selects the target antigen ...


Go Top